Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers
Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers
نویسندگان: مسعود فرشباف آقاجانی , سولماز مجردجبلی , سالار همتی , احمد یاری خسروشاهی , امیر ضارب کهن , هادی ولیزاده
کلمات کلیدی: Glioma, BBB, BBTB, Targeted drug delivery, D8, RI-VAP, NLCs
نشریه: 55299 , 2022 , 345 , 2022
| نویسنده ثبت کننده مقاله |
هادی ولیزاده |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
مرکز تحقیقات کاربردی دارویی |
| کد مقاله |
78358 |
| عنوان فارسی مقاله |
Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers |
| عنوان لاتین مقاله |
Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers |
| ناشر |
7 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
بلی |
| عنوان نشریه (خارج از لیست فوق) |
|
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| The effective treatment of glioma through conventional chemotherapy is proved to be a great challenge in clinics.
The main reason is due to the existence of two physiological and pathological barriers respectively including the
blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) that prevent most of the chemotherapeutics
from efficient delivery to the brain tumors. To address this challenge, an ideal drug delivery system would
efficiently traverse the BBB and BBTB and deliver the therapeutics into the glioma cells with high selectivity.
Herein, a targeted delivery system was developed based on nanostructured lipid carriers (NLCs) modified with
two proteolytically stable D-peptides, D8 and RI-VAP (Dual NLCs). D8 possesses high affinity towards nicotine
acetylcholine receptors (nAChRs), overexpressed on brain capillary endothelial cells (BCECs), and can penetrate
through the BBB with high efficiency. RI-VAP is a specific ligand of cell surface GRP78 (csGRP78), a specific
angiogenesis and cancer cell-surface marker, capable of circumventing the BBTB with superior glioma-homing
property. Dual NLCs could internalize into BCECs, tumor neovascular endothelial cells, and glioma cells with
high specificity and could penetrate through in vitro BBB and BBTB models with excellent efficiency compared to
non-targeted or mono-targeted NLCs. In vivo whole-animal imaging and ex vivo imaging further confirmed the
superior targeting capability of Dual NLCs towards intracranial glioma. When loaded with Bortezomib (BTZ),
Dual NLCs attained the highest therapeutic efficiency by means of superior in vitro cytotoxicity and apoptosis and
prolonged survival rate and efficient anti-glioma behavior in intracranial glioma-bearing mice. Collectively, the
designed targeting platform in this study could overcome multiple barriers and effectively deliver BTZ to glioma
cells, which represent its potential for advanced brain cancer treatment with promising therapeutic outcomes. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers.pdf | 1401/01/04 | 15541264 | دانلود |